Trial Profile
Phase 1 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Oct 2022
Price :
$35
*
At a glance
- Drugs Entinostat (Primary) ; Exemestane
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Kyowa Kirin
- 17 Jun 2022 Status changed from active, no longer recruiting to completed.
- 11 Mar 2019 Planned End Date changed from 1 Feb 2019 to 1 Dec 2021.
- 11 Mar 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Dec 2021.